Affiliation:
1. Department of Neurology Aomori Prefectural Central Hospital Aomori Japan
2. Department of Neurology Juntendo University Tokyo Japan
3. Department of Neurology Institute of Brain Science, Hirosaki University Graduate School of Medicine Hirosaki Japan
Abstract
AbstractLevodopa‐carbidopa intestinal gel therapy (LCIG), an effective treatment for advanced Parkinson's disease, can cause peripheral neuropathy. We present a 39‐year‐old man with LCIG‐related neuropathy with de novo diabetes mellitus (DM), decreased vitamin B6 and folate levels, and elevated homocysteine levels that developed over 2 years of LCIG treatment. Physicians should assess levels of levodopa metabolism‐associated vitamins and monitor risk factors of peripheral neuropathy, such as DM, before and after LCIG initiation.
Subject
Neurology (clinical),Neurology